GRECCAR 8: Impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: A randomized multicentre study

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Cotte, Eddy ^a,b   Villeneuve, Laurent ^b,c   Passot, Guillaume ^a,b   Boschetti, Gilles ^a   Bin Dorel, Sylvie ^c   Francois, Yves ^a,b   Glehen, Olivier ^a,b   Rullier, Eric ^d   Rouanet, Philippe ^e   Panis, Yves ^f   Tuech, Jean Jacques ^g   De Chaisemartin, Cécile ^h   Sielezneff, Igor ⁱ   Kirzin, Sylvain ^j   Faucheron, Jean luc ^k   Pezet, Denis ^l   Mariette, Christophe ^m   Regimbeau, Jean Marc ⁿ   Rivoire, Michel ^o   Lefevre, Jéremie ^p   Meunier, Bernard ^q   Deplanque, Gaël ^r   Porcheron, Jack ^s   Ortega Deballon, Pablo ^t   Pocard, Marc ^u   Bereder, Jean Marc ^v   Baranger, Bernard ^w   Evrard, Serge ^x   Paineau, Jacques ^y   Kianmanesh, Reza ^z   Tougeron, David ^aa   more..

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d HÔPITAL SAINT ANDRÉ   (France)

^e CENTRE VAL D AURELLE   (France)

^f BEAUJON HOSPITAL   (France)

^g ROUEN UNIVERSITY HOSPITAL   (France)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ TIMONE HOSPITAL   (France)

^j TOULOUSE UNIVERSITY HOSPITAL   (France)

^k HÔPITAL MICHALLON   (France)

^l UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^m LILLE UNIVERSITY HOSPITAL   (France)

ⁿ AMIENS UNIVERSITY HOSPITAL   (France)

^o CENTRE LÉON BÉRARD   (France)

^p HÔPITAL SAINT ANTOINE   (France)

^q RENNES UNIVERSITY HOSPITAL   (France)

^r SAINT JOSEPH HOSPITAL   (France)

^s UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^t DIJON UNIVERSITY HOSPITAL   (France)

^u HÔPITAL LARIBOISIÈRE   (France)

^v UNIVERSITY HOSPITAL OF NICE   (France)

^w INSTITUT CURIE   (France)

^x INSTITUT BERGONIÉ   (France)

^y UMR INSERM U892 CNRS 6299   (France)

^z REIMS UNIVERSITY HOSPITAL   (France)

^aa POITIERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Palliative treatment; Primary tumor resection; Quality of life; Rectal cancer; Survival; Unresectable metastasis

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; EMERGENCY SURGERY; FOLLOW UP; HUMAN; METASTASIS; MORBIDITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; RECTUM SURGERY; SURGICAL MORTALITY; TREATMENT RESPONSE; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPLICATION; DISEASE MANAGEMENT; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RECTAL NEOPLASMS; TREATMENT OUTCOME;

CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; HUMANS; MORBIDITY; MORTALITY; NEOPLASM METASTASIS; NEOPLASM STAGING; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84924064758     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1060-0     Document Type: Article

References (60)

1. Belot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, Delafosse P, et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique. 2008;56(3):159-75.
2. Verberne CJ, de Bock GH, Pijl ME, Baas PC, Siesling S, Wiggers T. Palliative resection of the primary tumour in stage IV rectal cancer. Colorectal Dis. 2012;14(3):314-9.
3. Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol. 2007;8(10):898-911.
4. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360(6):563-72.
5. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229-37.
6. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-17.
7. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20(11):1842-7.
8. Zampino MG, Magni E, Massacesi C, Zaniboni A, Martignetti A, Zorzino L, et al. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer. 2007;110(4):752-8.
9. Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol. 1999;6(7):651-7.
10. Ruo L, Gougoutas C, Paty PB, Guillem JG, Cohen AM, Wong WD. Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg. 2003;196(5):722-8.
11. Tebbutt NC, Norman AR, Cunningham D, Hill ME, Tait D, Oates J, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut. 2003;52(4):568-73.
12. Michel P, Roque I, Di Fiore F, Langlois S, Scotte M, Teniere P, et al. Colorectal cancer with non-resectable synchronous metastases: should the primary tumor be resected? Gastroenterol Clin Biol. 2004;28(5):434-7.
13. Mik M, Dziki L, Galbfach P, Trzcinski R, Sygut A, Dziki A. Resection of the primary tumour or other palliative procedures in incurable stage IV colorectal cancer patients? Colorectal Dis. 2010;12(7 Online):e61-7.
14. Law WL, Chan WF, Lee YM, Chu KW. Non-curative surgery for colorectal cancer: critical appraisal of outcomes. Int J Colorectal Dis. 2004;19(3):197-202.
15. Bajwa A, Blunt N, Vyas S, Suliman I, Bridgewater J, Hochhauser D, et al. Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. Eur J Surg Oncol. 2009;35(2):164-7.
16. Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg. 2005;92(9):1155-60.
17. Stelzner S, Hellmich G, Koch R, Ludwig K. Factors predicting survival in stage IV colorectal carcinoma patients after palliative treatment: a multivariate analysis. J Surg Oncol. 2005;89(4):211-7.
18. Karoui M, Roudot-Thoraval F, Mesli F, Mitry E, Aparicio T, Des Guetz G, et al. Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study. Dis Colon Rectum. 2011;54(8):930-8.
19. Kaufman MS, Radhakrishnan N, Roy R, Gecelter G, Tsang J, Thomas A, et al. Influence of palliative surgical resection on overall survival in patients with advanced colorectal cancer: a retrospective single institutional study. Colorectal Dis. 2008;10(5):498-502.
20. Konyalian VR, Rosing DK, Haukoos JS, Dixon MR, Sinow R, Bhaheetharan S, et al. The role of primary tumour resection in patients with stage IV colorectal cancer. Colorectal Dis. 2007;9(5):430-7.
21. Chan TW, Brown C, Ho CC, Gill S. Primary tumor resection in patients presenting with metastatic colorectal cancer: analysis of a provincial population-based cohort. Am J Clin Oncol. 2010;33(1):52-5.
22. Costi R, Mazzeo A, Di Mauro D, Veronesi L, Sansebastiano G, Violi V, et al. Palliative resection of colorectal cancer: does it prolong survival? Ann Surg Oncol. 2007;14(9):2567-76.
23. Yun HR, Lee WY, Lee WS, Cho YB, Yun SH, Chun HK. The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patient's status. Int J Colorectal Dis. 2007;22(11):1301-10.
24. Galizia G, Lieto E, Orditura M, Castellano P, Imperatore V, Pinto M, et al. First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg. 2008;143(4):352-8. discussion 358.
25. Evans MD, Escofet X, Karandikar SS, Stamatakis JD. Outcomes of resection and non-resection strategies in management of patients with advanced colorectal cancer. World J Surg Oncol. 2009;7:28.
26. Frago R, Kreisler E, Biondo S, Salazar R, Dominguez J, Escalante E. Outcomes in the management of obstructive unresectable stage IV colorectal cancer. Eur J Surg Oncol. 2010;36(12):1187-94.
27. Aslam MI, Kelkar A, Sharpe D, Jameson JS. Ten years experience of managing the primary tumours in patients with stage IV colorectal cancers. Int J Surg. 2010;8(4):305-13.
28. Venderbosch S, de Wilt JH, Teerenstra S, Loosveld OJ, van Bochove A, Sinnige HA, et al. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol. 2011;18(12):3252-60.
29. Ferrand F, Malka D, Bourredjem A, Allonier C, Bouche O, Louafi S, et al. Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Federation Francophone de Cancerologie Digestive 9601. Eur J Cancer. 2013;49(1):90-7.
30. Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg. 2010;34(4):797-807.
31. Gresham G, Renouf DJ, Chan M, Kennecke HF, Lim HJ, Brown C, et al. Association between palliative resection of the primary tumor and overall survival in a population-based cohort of metastatic colorectal cancer patients. Ann Surg Oncol. 2014;21(12):3917-23.
32. Ishihara S, Hayama T, Yamada H, Nozawa K, Matsuda K, Miyata H, et al. Prognostic impact of primary tumor resection and lymph node dissection in stage IV colorectal cancer with unresectable metastasis: a propensity score analysis in a multicenter retrospective study. Ann Surg Oncol. 2014;21(9):2949-55.
33. Legendre H, Vanhuyse F, Caroli-Bosc FX, Pector JC. Survival and quality of life after palliative surgery for neoplastic gastrointestinal obstruction. Eur J Surg Oncol. 2001;27(4):364-7.
34. Longo WE, Virgo KS, Johnson FE, Oprian CA, Vernava AM, Wade TP, et al. Risk factors for morbidity and mortality after colectomy for colon cancer. Dis Colon Rectum. 2000;43(1):83-91.
35. Makela J, Haukipuro K, Laitinen S, Kairaluoma MI. Palliative operations for colorectal cancer. Dis Colon Rectum. 1990;33(10):846-50.
36. Costi R, Di Mauro D, Veronesi L, Ardizzoni A, Salcuni P, Roncoroni L, et al. Elective palliative resection of incurable stage IV colorectal cancer: who really benefits from it? Surg Today. 2011;41(2):222-9.
37. Kleespies A, Fuessl KE, Seeliger H, Eichhorn ME, Muller MH, Rentsch M, et al. Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis. 2009;24(9):1097-109.
38. Rosen SA, Buell JF, Yoshida A, Kazsuba S, Hurst R, Michelassi F, et al. Initial presentation with stage IV colorectal cancer: how aggressive should we be? Arch Surg. 2000;135(5):530-4. discussion 534-535.
39. Stillwell AP, Buettner PG, Siu SK, Stitz RW, Stevenson AR, Ho YH. Predictors of postoperative mortality, morbidity, and long-term survival after palliative resection in patients with colorectal cancer. Dis Colon Rectum. 2011;54(5):535-44.
40. Vibert E, Bretagnol F, Alves A, Pocard M, Valleur P, Panis Y. Multivariate analysis of predictive factors for early postoperative death after colorectal surgery in patients with colorectal cancer and synchronous unresectable liver metastases. Dis Colon Rectum. 2007;50(11):1776-82.
41. Yamamura T, Tsukikawa S, Akaishi O, Tanaka K, Matsuoka H, Hanai A, et al. Multivariate analysis of the prognostic factors of patients with unresectable synchronous liver metastases from colorectal cancer. Dis Colon Rectum. 1997;40(12):1425-9.
42. Karoui M, Soprani A, Charachon A, Delbaldo C, Vigano L, Luciani A, et al. Primary chemotherapy with or without colonic stent for management of irresectable stage IV colorectal cancer. Eur J Surg Oncol. 2010;36(1):58-64.
43. Sarela AI, Guthrie JA, Seymour MT, Ride E, Guillou PJ, O'Riordain DS. Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. Br J Surg. 2001;88(10):1352-6.
44. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23-30.
45. Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer. 2007;7:91.
46. Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol. 2008;62(2):195-201.
47. Muratore A, Zorzi D, Bouzari H, Amisano M, Massucco P, Sperti E, et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol. 2007;14(2):766-70.
48. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol. 2009;27(20):3379-84.
49. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007-16.
50. Eisenberger A, Whelan RL, Neugut AI. Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review. Int J Colorectal Dis. 2008;23(6):559-68.
51. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539-44.
52. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-42.
53. Ghiringhelli F, Bichard D, Limat S, Lorgis V, Vincent J, Borg C, et al. Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection. Ann Surg Oncol. 2014;21(5):1632-40.
54. Vigano L, Capussotti L, Barroso E, Nuzzo G, Laurent C, Ijzermans JN, et al. Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases. Ann Surg Oncol. 2012;19(9):2786-96.
55. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240(6):1052-61. discussion 1061-1054.
56. Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7(1):109-15. discussion 116-107.
57. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26(11):1830-5.
58. Stelzner S, Hellmich G, Jackisch T, Ludwig K, Witzigmann H. Selective surgical treatment of patients with rectal carcinoma and unresectable synchronous metastases based on response to preoperative chemotherapy. J Gastrointest Surg. 2008;12(7):1246-50.
59. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-13.
60. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.